No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 196 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... August 4, 2021 Pazopanib Is Not Inferior to Doxorubicin in First-Line Treatment of Elderly... August 31, 2020 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma July 31, 2020 The Growths On This Woman’s Lips Are A Sign That She... April 17, 2020 Load more HOT NEWS ΠΟΝΟΣ Dad Is Making Baby Giggle, But When He Makes A Sheep... Talking About Sexual Health Concerns With Your Cancer Care Team: How... FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma
